Lexicon Pharmaceuticals (NASDAQ:LXRX) Now Covered by StockNews.com

StockNews.com began coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX - Free Report) in a research note published on Friday. The firm issued a sell rating on the biopharmaceutical company's stock.

A number of other brokerages have also issued reports on LXRX. HC Wainwright restated a "buy" rating and issued a $4.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Monday, March 3rd. Leerink Partnrs downgraded shares of Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Needham & Company LLC reissued a "hold" rating on shares of Lexicon Pharmaceuticals in a research report on Monday, March 3rd. Piper Sandler dropped their target price on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating on the stock in a report on Friday, March 7th. Finally, Leerink Partners reissued a "market perform" rating and issued a $1.00 target price (down from $2.00) on shares of Lexicon Pharmaceuticals in a research note on Tuesday, March 4th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $3.67.

Remove Ads

Lexicon Pharmaceuticals Price Performance

Shares of LXRX traded up $0.22 during trading hours on Friday, reaching $0.57. 404,600,887 shares of the company's stock traded hands, compared to its average volume of 5,606,431. Lexicon Pharmaceuticals has a 12 month low of $0.28 and a 12 month high of $2.45. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56. The stock has a market cap of $140.48 million, a PE ratio of -0.76 and a beta of 1.04. The firm's 50 day simple moving average is $0.61 and its 200-day simple moving average is $1.00.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. The firm had revenue of $26.55 million for the quarter, compared to analyst estimates of $6.48 million. Equities analysts expect that Lexicon Pharmaceuticals will post -0.66 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bayesian Capital Management LP purchased a new stake in Lexicon Pharmaceuticals during the 4th quarter valued at $31,000. RPO LLC bought a new stake in shares of Lexicon Pharmaceuticals in the fourth quarter worth $33,000. Renaissance Technologies LLC purchased a new stake in Lexicon Pharmaceuticals during the fourth quarter valued at $38,000. Arizona State Retirement System lifted its holdings in Lexicon Pharmaceuticals by 34.4% in the fourth quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 16,136 shares during the period. Finally, Teacher Retirement System of Texas boosted its position in Lexicon Pharmaceuticals by 60.3% in the fourth quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company's stock worth $48,000 after purchasing an additional 24,615 shares during the last quarter. Institutional investors own 74.70% of the company's stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.